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Potassium-magnesium citrate versus potassium chloride in uretic therapy is hypokalemia, which is reported to occur
thiazide-induced hypokalemia. in about half of the patients on chronic thiazide treat-
Background. The purpose of this study was to compare the ment [2]. Although less well appreciated, thiazide mayvalue of potassium-magnesium citrate (KMgCit) with potas-
also provoke renal magnesium loss [3] and hypocitraturiasium chloride in overcoming thiazide-induced hypokalemia.
[4]. The resulting magnesium depletion may exaggerateMethods. Sixty normal subjects first took hydrochlorothia-
zide (HCTZ; 50 mg/day). After three weeks of treatment (or neuromuscular and cardiac side-effects of hypokalemia,
earlier if hypokalemia developed), they were randomized to including muscle weakness, paralysis, and arrhythmia
take KMgCit (42 mEq K, 21 mEq Mg, and 63 mEq citrate/ [5]. Magnesium depletion may also blunt the ability ofday) or potassium chloride (42 mEq/day) for three weeks while
potassium chloride to correct hypokalemia [6]. In the man-continuing on HCTZ.
agement of stone disease, the beneficial hypocalciuric ac-Results. KMgCit significantly increased the serum potassium
concentration from 3.42 6 0.30 mEq/L on HCTZ alone to tion of thiazide may be opposed by the reduction in uri-
about 3.8 mEq/L (P , 0.001). Potassium chloride produced a nary citrate, an inhibitor of stone formation [7].
similar increase in serum potassium concentration from 3.45 6 It is customary to treat hypokalemia of thiazide ther-0.44 mEq/L to about 3.8 mEq/L (P , 0.001). KMgCit signifi-
apy with potassium chloride supplementation. Unfortu-cantly increased the serum magnesium concentration by 0.11 to
nately, potassium chloride does not prevent or correct0.12 mEq/L (P , 0.01), whereas potassium chloride produced a
marginal decline or no significant change. KMgCit was less magnesium depletion. Moreover, potassium chloride it-
effective than potassium chloride in correcting HCTZ-induced self has no effect on urinary citrate excretion [8] and
hypochloridemia and hyperbicarbonatemia. KMgCit, but not only modestly increases urinary citrate in the setting ofpotassium chloride, significantly increased urinary pH (by
hypokalemia [4].about 0.6 unit), citrate (by about 260 mg/day), and urinary
magnesium. Recent studies suggest that potassium-magnesium ci-
Conclusions. KMgCit is equally effective as potassium chlo- trate (KMgCit), formulated for the prevention of cal-
ride in correcting thiazide-induced hypokalemia. In addition, cium-containing renal stones [9, 10], may be advanta-
KMgCit, but not potassium chloride, produces a small but
geous over potassium chloride as an adjunctive agent tosignificant increase in serum magnesium concentration by de-
be used with thiazide. In normal subjects undergoing alivering a magnesium load, and it confers alkalinizing and citra-
turic actions. short-term thiazide treatment, the coadministration of
KMgCit has been shown to ameliorate hypokalemia and
to produce a small but significant increase in the serum
Thiazide is widely used for the control of essential magnesium concentration [11–13]. Moreover, it substan-
hypertension and fluid retention. Thiazide is also fre- tially increased urinary citrate by providing an alkali
quently employed in the treatment of hypercalciuric load. However, these studies compared KMgCit with
nephrolithiasis, because it can correct hypercalciuria by potassium citrate or magnesium citrate, but not with the
enhancing renal tubular reabsorption of calcium [1]. A standard of care, potassium chloride.
frequent and potentially serious complication of this di- We therefore sought to compare the efficacy of
KMgCit with potassium chloride in treating thiazide-
induced hypokalemia. We found that KMgCit is equallyKey words: hypercalciuric nephrolithiasis, diuretic therapy, hypoka-
lemia, hypomagnesemia. effective as potassium chloride in correcting thiazide-
induced hypokalemia, and unlike potassium chloride,Received for publication March 23, 1999
KMgCit enhances urinary citrate excretion and producesand in revised form August 30, 1999
Accepted for publication September 9, 1999 a small but significant increase in the serum magnesium
concentration.Ó 2000 by the International Society of Nephrology
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METHODS cal in appearance and size, both medications were pre-
pared as wax matrix formulations by the Mission Phar-Clinical data
macal Company (San Antonio, TX, USA). KMgCit is
This study was approved by the Institutional Review an investigational drug (IND 36,276) for which the Uni-
Board of the University of Texas Southwestern Medical versity of Texas Southwestern Medical Center is the
Center. Normal adult volunteers were recruited for this sponsor, and one of the authors (C.Y.C.P.) is the princi-
double-blind randomized trial by fliers and word of pal investigator. None of the investigators own equity
mouth. or consult for Mission. Mission has provided partial re-
After obtaining informed consent, subjects were search support, as well as a free supply of investigational
screened by history, physical examination, serum chemis- drugs.
try, complete blood counts, electrocardiogram, occult Subjects were evaluated in an outpatient setting, be-
blood in feces, and 24-hour urinary chemistries. Subjects fore thiazide treatment, and weekly thereafter (1 to 3
were excluded from the study if they had hypokalemia weeks of HCTZ alone, 3 weeks of HCTZ plus KMgCit
or hyperkalemia, hypomagnesemia, creatinine clearance or potassium chloride). At each visit, a venous blood
of less than 0.9 mL/min/kg, anemia, occult blood in feces, sample was drawn before lunch, to correspond to 4.5
or arrhythmia. They did not have history of renal stones, hours after taking HCTZ and the morning dose of
other kidney diseases or peptic ulcer disease. They were KMgCit or potassium chloride, for the measurement of
not taking any potassium or magnesium supplements or potassium, magnesium, chloride, and bicarbonate. Urine
medications that could alter potassium or magnesium was collected in a 24-hour pool for the analysis of pH,
metabolism. citrate, and magnesium. Stool was examined for occult
blood before (pre-HCTZ) and at the conclusion (3 weeksExperimental design
of HCTZ and supplement) of the study by using the
The basic experimental design was described pre- Hemoccult test. At each visit, a side-effect questionnaire
viously [11–13]. The study was divided into two phases [11–13] was completed that addressed 14 gastrointestinal
conducted in sequence. Hydrochlorothiazide (HCTZ) symptoms [11] and four symptoms of hypokalemia or
alone was given in phase I (HCTZ phase). In phase II volume depletion [11]. Each side effect was rated from
(supplement phase), HCTZ was provided with a potas- one (none) to four (.7 episodes per week) for frequency
sium supplement (KMgCit or potassium chloride). Sub- and one (none) to four (severe) for severity. Thus, the
jects were instructed on a diet with a daily composition lowest score was one and the highest was four for each
of approximately 45 to 55 mEq potassium, 160 to 200 symptom.
mg (13.2 to 16.4 mEq) magnesium, 90 to 120 mEq so- Serum potassium was measured by using an ion-spe-
dium, 120 to 150 mEq chloride, and 3 L fluids. The cific electrode and serum magnesium by atomic absorp-
adherence to this diet was reinforced at each visit. tion spectrophotometry in the laboratory of the General
In phase I, all subjects were placed on HCTZ 50 mg Clinical Research Center. Serum chloride and total car-
with breakfast each day. They were evaluated weekly bon dioxide (bicarbonate) were measured as a part of
for the measurement of serum potassium. Subjects who multichannel screen with an autoanalyzer. Urinary mag-
developed hypokalemia (serum K , 3.5 mEq/L) during nesium was analyzed by atomic absorption spectropho-
the first two weeks of treatment with HCTZ alone imme- tometry and citrate was analyzed by the citrate lyase
diately entered phase II. Subjects who completed three method in the Mineral Metabolism Laboratory.
weeks of treatment with HCTZ alone entered phase II
Statistical analysiswhether or not they developed hypokalemia.
During phase II, subjects continued to take HCTZ (50 For blood and urinary parameters, repeated-measures
mg/day) with breakfast for three more weeks. They were analysis of variance with a grouping factor for the two
randomized between KMgCit and potassium chloride treatment groups and a repeated factor for five measure-
groups, stratified according to gender. Subjects in ments (phases: pretreatment, last week of HCTZ, week
KMgCit group took KMgCit three tablets with breakfast 1, week 2, and week 3 of supplement with HCTZ) was
and three tablets with dinner, delivering 42 mEq K, 21 used to assess differences in response between the two
mEq Mg, and 63 mEq citrate per day for three weeks. study groups. A significant interaction between treat-
Those in the potassium chloride group received three ment and phase (visit) indicates that the responses to the
tablets of potassium chloride with breakfast and three different treatments are not the same. Within a treatment
tablets with dinner, providing 42 mEq of potassium and group, multiple comparisons were made by using paired
chloride each day for three weeks. t-tests to compare the last week of HCTZ phase with
Each tablet of KMgCit contained 7 mEq K, 3.5 mEq each week of supplement phase (HCTZ plus KMgCit
Mg, and 10.5 mEq citrate; a tablet of potassium chloride or potassium chloride) and with the pretreatment phase.
For interpreting these multiple comparisons, a signifi-contained 7 mEq each of potassium and chloride. Identi-
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Table 1. Baseline presentations of 60 subjects Serum chemistries
Potassium On HCTZ alone, 44 of 60 subjects (23 in KMgCit and
KMgCit chloride 21 in potassium chloride) developed hypokalemia. The
No. subjects 30 30 mean serum potassium concentration significantly de-
No. female/no. male 22/8 23/7
creased by 0.72 mEq/L in the KMgCit group and by 0.67Age years 36613 35610
Weight kg 77613 82620 mEq/L in the potassium chloride group (Fig. 1A). During
Height cm 1716101 167612 the supplement phase, the serum potassium concentra-
Serum
tion increased significantly by 0.34 to 0.43 mEq/L in thePotassium mEq/L 4.260.4 4.160.5
Magnesium mg/dL 2.060.2 2.060.2 KMgCit group and by 0.35 to 0.44 mEq/L in the potas-
Urinary sium chloride group. The serum potassium concentration
Potassium mEq/day 52622 44614
was maintained within normal limits or was normalizedMagnesium mg/day 92651 91634
pH 6.0560.47 6.0960.38 (.3.5 mEq/L) in 76 and 71% of determinations in the
Citrate mg/day 6406299 5876238 KMgCit and potassium chloride groups, respectively. No
Endogenous Cr 119633 121634
significant difference was disclosed between the twoClearance mL/min
groups.Abbreviation is: Cr, creatinine. To convert urinary magnesium to mEq/day,
divide value in mg/day by 12.16. To convert citrate to mEq/day, divide value in During treatment with HCTZ alone, the mean serum
mg/day by 63. Hypokalemia 5 serum potassium #3.5 mEq/L; hyperkalemia 5 chloride concentration decreased significantly in bothserum potassium .5.5 mEq/L; hypomagnesemia 5 serum magnesium #1.5 mEq/L
or 1.8 mg/dL. groups (Fig. 1B). When KMgCit was added, a significant
increase in serum chloride concentration was disclosed
at three weeks but not during the first two weeks. The
serum chloride concentration increased significantly to-cance level of 0.01 was used to adjust for multiplicity of
ward the prethiazide range during all three weeks oftesting.
potassium chloride supplementation from HCTZ alone.For side effect frequency and severity scores, the Wil-
With both supplementations, the serum chloride concen-coxon signed-rank test was performed for the compari-
tration remained below the prethiazide values. Differ-son of HCTZ alone within each group, and the Wilcoxon
ences between the two groups were significant duringRank Sum statistic was employed for comparing KMgCit
the supplement phase (analysis of variance, P , 0.01).with potassium chloride. The 0.05 level of significance
Treatment with HCTZ alone significantly increasedwas used for these comparisons to avoid a type II error.
serum bicarbonate concentration in both groups (Fig.Results are presented as mean 6 sd. Analyses were
1C). During KMgCit supplementation, the serum bicar-performed by using SAS version 6.12 (SAS Institute,
bonate concentration significantly decreased at threeCary, NC, USA).
weeks from HCTZ alone but not during the first two
weeks. In contrast, potassium chloride supplementation
RESULTS significantly decreased serum bicarbonate concentration
during all three weeks. The change in serum bicarbonateDemography and baseline presentation
concentration was significantly different between the twoSixty-five subjects were enrolled in the trial, allowing
groups (ANOVA, P 5 0.01).for an anticipated withdrawal of five subjects. A decision
The mean serum magnesium concentration did notwas made to close the trial in mid-December 1998 when
decrease significantly during HCTZ alone in either group60 subjects completed all three weeks of the supplement
(Fig. 1D). During supplement phase, the addition ofphase. During the first week of HCTZ alone, two subjects
KMgCit to the ongoing HCTZ treatment produced awithdrew because of side effects of thiazide, and one
small but significant increase in serum magnesium con-subject withdrew because of an unwillingness to follow
centration of 0.11 to 0.12 mEq/L. In contrast, serumthe diet. The fourth subject withdrew before starting
magnesium concentration did not change significantly orHCTZ from an exacerbation of pre-existing spastic coli-
decreased marginally during potassium chloride supple-tis. The fifth subject had successfully finished three weeks
mentation (P 5 0.07 at 2 weeks). During the supplementof HCTZ phase in mid-December 1998. We decided to
phase, the serum magnesium concentration was signifi-withdraw her from the trial, anticipating difficulty in
cantly different between the two groups (ANOVA, P 5adherence to the diet during the holiday season.
0.0002).Demographic and baseline data are presented for 60
subjects who completed the trial in Table 1. There were
Urinary chemistries30 subjects in each group (KMgCit or potassium chlo-
The mean urinary pH did not change significantly onride). The two groups did not differ with respect to gen-
HCTZ alone (Table 2). During the supplement phase,der ratio, age, weight, and height. Serum and urinary
chemistries did not differ between the two groups. it increased significantly when KMgCit was added to the
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Fig. 1. (A) Effect of potassium-magnesium citrate (KmgCit; d) and potassium chloride (s) on serum potassium concentration. After hypokalemia
developed from treatment with hydrochlorothiazide (HCTZ) alone, supplementation with either KMgCit or potassium chloride was provided for
three weeks while HCTZ was continued. Within each group, the significance of difference from HCTZ alone was determined. †P , 0.001 from
HCTZ alone within the same groups. (B) Effect of KMgCit or potassium chloride on serum chloride concentration. *P , 0.05 from HCTZ alone
within the same group. (C) Effect of KMgCit or potassium chloride on serum bicarbonate concentration. **P , 0.01 from HCTZ alone within
the same group. (D) Effect of KMgCit or potassium chloride on the serum magnesium concentration.
ongoing HCTZ treatment by about 0.6. In contrast, no Safety and other results
significant change in urinary pH developed during potas- Individual gastrointestinal scores were one (lowest
sium chloride supplementation. Differences between the value) or close to one throughout the study (prethiazide,
two groups were significant (ANOVA, P , 0.0001). HCTZ alone, and supplement phase) in both KMgCit
The mean urinary citrate decreased significantly in and potassium chloride groups. There was a small but sig-
both groups during HCTZ alone (Table 2). It increased nificant increase in scores for nausea, anorexia, and con-
significantly during supplementation with KMgCit (by
stipation from prethiazide to HCTZ alone by about 0.2
about 260 mg/day), but not with potassium chloride. Be-
unit (P , 0.05). No significant difference in frequency andtween-group differences during supplementation were
severity scores for any side effect was disclosed betweensignificant (ANOVA, P 5 0.0004).
HCTZ alone and supplement phase in either group.Urinary magnesium increased significantly by about
On HCTZ alone, individual scores for muscle weak-25 mg (2.1 mEq)/day following KMgCit supplementation
ness, muscle cramping, and dizziness increased signifi-(P , 0.01), but did not change significantly after potas-
cantly by 0.2 to 0.5 unit in both groups (P 5 0.05 tosium chloride supplementation (Table 2). Differences
0.001). Scores for muscle weakness and cramping de-between the two groups were significant (ANOVA, P 5
creased significantly during supplementation with KMgCit0.0007). Urinary potassium increased significantly fol-
from HCTZ alone (P 5 0.05 to 0.01). The scores forlowing supplementation with KMgCit supplementation
(P , 0.001) and potassium chloride (P , 0.05). muscle weakness and dizziness declined significantly fol-
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Table 2. Urinary response found to be equally effective as potassium chloride in
correcting or ameliorating hypokalemia. However, un-Potassium
KMgCit chloride like potassium chloride, KMgCit produced a small but
N Mean SD N Mean SD significant increase in serum magnesium concentration
by providing bioavailable magnesium and exerted alka-Urinary pHd
Pretreatment 29 6.0560.47 30 6.0960.38 linizing and citraturic actions. Both KMgCit and potas-
Last week of HCTZ alone 30 5.9660.34 30 5.9660.43 sium chloride were well tolerated, with both supplements
Week 1 of supplement 29 6.5060.39c 30 5.9660.42
ameliorating adverse symptoms of thiazide treatment.Week 2 of supplement 29 6.5560.43c 30 5.9760.45
Week 3 of supplement 30 6.5660.43c 30 5.9660.48 The equal efficacy of KMgCit and potassium chloride
Urinary citrated mg/day in correcting thiazide-induced hypokalemia allays con-
Pretreatment 29 6406299a 30 5876238b
cern that the provision of chloride anion with potassiumLast week of HCTZ alone 30 5026245 30 4626192
Week 1 of supplement 28 7186349c 30 5116208 supplementation is critical for the restoration of normal
Week 2 of supplement 29 7686338c 30 5376231 serum potassium concentration. When a citrate anion is
Week 3 of supplement 30 7646314c 30 5236199
provided as with KMgCit, an earlier study [14] suggestedUrinary Mgd mg/day
Pretreatment 29 92651 30 91634 that a relatively poor renal tubular reabsorption of ci-
Last week of HCTZ alone 30 88637 30 89640 trate would cause an enhanced renal tubular secretion
Week 1 of supplement 29 110662b 30 82627
of potassium, impairing the correction of hypokalemia.Week 2 of supplement 29 117652c 30 88637
Week 3 of supplement 30 115654b 30 90637 However, a more recent study has disclosed that renal
Urinary K mEq/day potassium leak occurs only in the setting of severe chlo-
Pretreatment 29 52622 30 44614
ride depletion with urinary chloride concentration of lessLast week of HCTZ alone 30 48622 30 48624
Week 1 of supplement 29 67631c 30 62626a than 15 mEq/L [15]. Such severe chloride depletion is
Week 2 of supplement 29 71630c 30 62629a rare, except in intractable diarrhea or vomiting or follow-
Week 3 of supplement 30 75631c 30 55624
ing protracted nasogastric suction. A significant chlorideUrinary Na mEq/day
Pretreatment 29 146661a 30 157683 depletion did not develop in our study, as urinary chlo-
Last week of HCTZ alone 30 175652 30 151675 ride exceeded 50 mEq/day in a vast majority of our
Week 1 of supplement 29 167663 30 1816102
subjects (unpublished observation). This finding couldWeek 2 of supplement 29 186687 30 190684a
Week 3 of supplement 30 1996108 30 1946107a explain the similar efficacy of KMgCit and potassium
Urinary Cl mmol/day chloride in correcting hypokalemia.
Pretreatment 29 138660a 30 152689
Both KMgCit and potassium chloride displayed a pic-Last week of HCTZ alone 30 167646 30 155672
Week 1 of supplement 29 157655 30 2096138a ture of mild metabolic alkalosis, with an incomplete re-
Week 2 of supplement 29 172679 30 210687b turn of serum concentrations of bicarbonate and chloride
Week 3 of supplement 30 1876100 30 2036107a
to the prethiazide values. The persistence of hypoka-
During 3 weeks of supplement phase, KMgCit or potassium chloride was
lemia in some patients and probable prevailing volumegiven with HCTZ.
Significant difference from HCTZ alone is shown by a for P , 0.05, b for P , depletion during a short-term thiazide therapy of four
0.01 and c for P , 0.001
to six weeks could partly account for mild metabolicd KMgCit versus potassium chloride (ANOVA), P , 0.001; urinary K, P 5
0.07; Na & Cl, P . 0.10 alkalosis in both groups. The more prolonged delay in the
correction of hyperbicarbonatemia and hypochloridemia
by KMgCit, compared with potassium chloride, could
be explained by the provision of citrate anion ratherlowing potassium chloride supplementation (P 5 0.05 to
than chloride anion, and delivery of an alkali load [8].0.01).
The presence of mild metabolic alkalosis duringBy pill count, compliance averaged 100% for HCTZ,
KMgCit supplementation should not pose a deleterious96% for KMgCit, and 98% for potassium chloride. One
clinical problem. Serum concentrations of bicarbonatesubject from the potassium chloride group had a positive
and chloride were within normal limits during KMgCittest for occult blood in feces during the supplement
supplementation. Small changes in serum bicarbonatephase, without anemia or symptoms of blood loss. Re-
and chloride shown with KMgCit in this trial have beenpeat testing was negative. No other subject had a positive
encountered during potassium citrate or potassium bi-test for occult blood in feces. Electrocardiograms, ob-
carbonate therapy of patients with urolithiasis [16], hy-tained when serum potassium was less than 3 mEq/L,
pertension [17], or of postmenopausal women (for pre-did not show abnormal changes.
vention of bone loss) [17], without known side effects.
The alkalinizing and citraturic effects displayed by
DISCUSSION KMgCit, but not by potassium chloride, justify the use
of potassium alkali over potassium chloride in patientsThis trial was undertaken in order to compare the
value of KMgCit with potassium chloride in the manage- with hypercalciuric nephrolithiasis treated with thiazide.
KMgCit not only prevents hypokalemia but increasesment of thiazide-induced hypokalemia. KMgCit was
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